Sectors
MCRB
Seres Therapeutics, Inc.
5.21
1 x 5.21
2 x 5.33
bid
ask
-
0.04
0.76%
10:05 AM
timesize
| Ytd | -64.99% | |
| 1y | -57.95% |
5.27
day range
5.27
5.00
52 week range
29.98
| Open | 5.27 | Prev Close | 5.25 | Low | 5.27 | High | 5.27 | Mkt Cap | 50.84M |
| Vol | 5.55K | Avg Vol | 86.41K | EPS | -5.30 | P/E | -0.99 | Forward P/E | -1.75 |
| Beta | 0.09 | Short Ratio | 5.18 | Inst. Own | 37.15% | Dividend | N/A | Div Yield | N/A |
| Ex Div Date | N/A | Earning | 08-05 | 50-d Avg | 6.92 | 200-d Avg | 11.85 | 1yr Est | 3.87 |
| Income Statement | |||
| Total Revenue | 358.00K | ||
| Revenues (USD) | 358.00K | ||
| Gross Profit | 358.00K | ||
| Operating Expenses | 21.27M | ||
| Research and Development Expense | 13.20M | ||
| Selling, General and Administrative Expense | 8.07M | ||
| Operating Income | -20.91M | ||
| Net Income | -19.91M | ||
| Net Income Common Stock | -19.91M | ||
| Net Income Common Stock (USD) | -19.91M | ||
| Consolidated Income | -19.91M | ||
| Earnings per Basic Share | -2.08 | ||
| Earnings per Basic Share (USD) | -2.08 | ||
| Earnings per Diluted Share | -2.08 | ||
| Earning Before Interest & Taxes (EBIT) | -19.91M | ||
| Earning Before Interest & Taxes (USD) | -19.91M | ||
| Weighted Average Shares | 9.58M | ||
| Weighted Average Shares Diluted | 9.58M | ||
| Balance Sheet | |||
| Cash and Equivalents | 38.50M | ||
| Cash and Equivalents (USD) | 38.50M | ||
| Trade and Non-Trade Receivables | 233.00K | ||
| Current Assets | 31.84M | ||
| Property, Plant & Equipment Net | 77.08M | ||
| Total Assets | 117.62M | ||
| Debt Current | 10.87M | ||
| Total Debt | 80.50M | ||
| Current Liabilities | 19.34M | ||
| Debt Non-Current | 69.63M | ||
| Total Liabilities | 91.12M | ||
| Accumulated Retained Earnings (Deficit) | -992.32M | ||
| Shareholders Equity | 26.50M | ||
| Shareholders Equity (USD) | 26.50M | ||
| Assets Non-Current | 85.78M | ||
| Total Debt (USD) | 80.50M | ||
| Liabilities Non-Current | 71.78M | ||
| Trade and Non-Trade Payables | 2.34M | ||
| Cash Flow | |||
| Depreciation, Amortization & Accretion | 3.04M | ||
| Net Cash Flow from Financing | 428.00K | ||
| Net Cash Flow / Change in Cash & Cash Equivalents | -15.93M | ||
| Issuance (Purchase) of Equity Shares | 428.00K | ||
| Net Cash Flow from Operations | -16.36M | ||
| Share Based Compensation | 1.77M | ||